Page 106 - Sohini Das

Price cap on cancer drugs likely to dent profit margins of hospitals

Industry insiders pointed out that almost 70% of oncology drugs are sold through the hospital channel

Sun Pharma net profit up four-fold to Rs 1,242 crore in Dec quarter

The company may also spend more on research and development (R&D) next year owing to clinical trials for new indications of its recently launched product Ilumya and others

Ashutosh Raghuvanshi appointed Fortis Healthcare CEO with effect from March

He replaces Bhavdeep Singh, who had tendered in his resignation as the CEO on November 8 last year citing professional and personal reasons

RCom goes to NCLT to speed up Jio deal, hopes move will expedite DoT nod

On Monday, RCom also moved the NCLAT to withdraw its opposition to an insolvency petition filed by Ericsson India in the NCLT

By March, a quarter of Reliance Jio subscribers to be JioPhone users

By 2021, analysts estimate over 40 per cent of Jio's subscribers would be smartphone users

Sun Pharma to settle Dubai firm loans, shift distribution arm to subsidiary

Sun Pharma in damage control mode after stock loses about 30% of its value since Sept due to corporate governance concerns

Regrow's cell therapy product gets orphan drug status from USFDA

Start-up in talks with MNCsto out-license Ossgrow for developed markets

Sun Pharma moves Sebi as stock dips on fresh whistle-blower allegations

Sun Pharma on Friday urged the markets regulator to examine the role of some media houses with regard to the allegations raised by the whistle-blower

Jio PAT beats Street estimates, up 65% y-o-y on robust user addition

RIL reiterated plans to hive off the fibre and tower businesses into separate companies to manage spend on these capex heavy business segments

Biocon likely to channelise investments towards non-insulin biologics

Globally, the insulin business has come under pressure

Indian pharma industry records 9.4% growth in 2018, dispels GST gloom

The industry performed better in 2018, in comparison, on a GST-impacted low base

Reliance Jio may capture 51% revenue market share in 3 years: Analysts

Airtel and Vodafone Idea are also trying to expand the penetration of fourth-generation technology (4G) users in their subscriber base as they take this network to the hinterland

DPCO amendment may benefit MNC device makers by allowing price control

Local industry fears global firms will register equipment as 'innovative' to secure price control waiver for 5 years

Natco Pharma shifts focus from US, to spend 70% funds in emerging markets

60-70% of the R&D spend will be for developing portfolio in Brazil, Canada, China & India

Reliance Jio to hive off fibre, tower businesses into separate companies

An analyst pointed out that of the Rs 4 trillion investment announced by Reliance Jio, about Rs 1.2 trillion is estimated to be for the fibre business

Reliance Jio continues to boost subscriber base in metros, Airtel hangs on

Reliance Jio is also banking on GigaFiber to get more subscribers in the metros

Pharma margins to get rupee boost in Q2, highlights report

This would also safeguard them from margin pressure, said the report

Avenue Supermarts' Q2 net profit up 18.3% at Rs 2.26 billion YoY

The company added three stores during the quarter

USFDA drug approvals at all-time high; Indian firms get 35-40% of nods

The regulator has bettered last year's numbers with 971 approval actions this year

After strong Q1, drug firms' revenue growth to dip to 7%, say analysts

The first quarter (Q1) of this financial year was a strong one for pharmaceutical players, driven by 28 per cent domestic growth on a GST-disrupted base